Relay Therapeutics (RLAY) Financials

$2.95 +0.10 (+3.51%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$2.90 -0.05 (-1.69%)

As of 05/28/2025 07:57 PM Eastern

Annual Income Statements for Relay Therapeutics

This table shows Relay Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-338	-342	-291
Consolidated Net Income / (Loss)	-338	-342	-291
Net Income / (Loss) Continuing Operations	-338	-342	-291
Total Pre-Tax Income	-338	-342	-291
Total Operating Income	-372	-373	-299
Total Gross Profit	10	26	1.38
Total Revenue	10	26	1.38
Operating Revenue	10	26	1.38
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	382	399	301
Selling, General & Admin Expense	77	75	66
Research & Development Expense	319	330	246
Other Operating Expenses / (Income)	-13	-6.42	-12
Total Other Income / (Expense), net	35	31	8.77
Interest & Investment Income	35	31	8.79
Other Income / (Expense), net	0.01	-0.02	-0.02
Basic Earnings per Share	($2.36)	($2.79)	($2.59)
Weighted Average Basic Shares Outstanding	142.87M	122.58M	112.23M
Diluted Earnings per Share	($2.36)	($2.79)	($2.59)
Weighted Average Diluted Shares Outstanding	142.87M	122.58M	112.23M
Weighted Average Basic & Diluted Shares Outstanding	169.52M	131.18M	121.38M

This table shows Relay Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-76	-88	-92	-81	-83	-66	-99	-94	-68	-84
Consolidated Net Income / (Loss)	-76	-88	-92	-81	-83	-66	-99	-94	-68	-84
Net Income / (Loss) Continuing Operations	-76	-88	-92	-81	-83	-66	-99	-94	-68	-84
Total Pre-Tax Income	-76	-88	-92	-81	-83	-66	-99	-94	-68	-84
Total Operating Income	-85	-96	-101	-90	-92	-74	-106	-101	-73	-86
Total Operating Expenses	85	96	101	100	92	99	106	101	73	86
Selling, General & Admin Expense	17	20	20	20	17	18	20	20	16	16
Research & Development Expense	68	77	92	82	77	81	88	83	67	67
Total Other Income / (Expense), net	8.98	8.26	8.55	8.98	8.70	7.84	7.55	6.94	5.35	1.72
Interest & Investment Income	8.97	8.27	8.55	8.95	8.70	7.85	7.56	6.94	5.37	1.71
Other Income / (Expense), net	0.00	-0.01	-0.00	0.03	0.00	-0.00	-0.01	-0.00	-0.02	0.01
Basic Earnings per Share	($0.42)	($0.63)	($0.69)	($0.62)	($0.66)	($0.54)	($0.81)	($0.78)	($0.55)	($0.76)
Weighted Average Basic Shares Outstanding	142.87M	140.23M	132.82M	130.84M	122.58M	122.23M	121.68M	121.32M	112.23M	110.91M
Diluted Earnings per Share	($0.42)	($0.63)	($0.69)	($0.62)	($0.66)	($0.54)	($0.81)	($0.78)	($0.55)	($0.76)
Weighted Average Diluted Shares Outstanding	142.87M	140.23M	132.82M	130.84M	122.58M	122.23M	121.68M	121.32M	112.23M	110.91M
Weighted Average Basic & Diluted Shares Outstanding	169.52M	167.38M	133.89M	132.74M	131.18M	123.27M	122.13M	121.61M	121.38M	120.89M

This table details how cash moves in and out of Relay Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-20	-7.93	-128
Net Cash From Operating Activities	-249	-300	-229
Net Cash From Continuing Operating Activities	-249	-300	-229
Net Income / (Loss) Continuing Operations	-338	-342	-291
Consolidated Net Income / (Loss)	-338	-342	-291
Depreciation Expense	5.46	5.27	4.13
Amortization Expense	-12	-11	1.18
Non-Cash Adjustments To Reconcile Net Income	94	86	56
Changes in Operating Assets and Liabilities, net	1.41	-39	-0.43
Net Cash From Investing Activities	-41	258	-189
Net Cash From Continuing Investing Activities	-41	258	-189
Purchase of Property, Plant & Equipment	-2.02	-4.13	-9.06
Purchase of Investments	-651	-386	-535
Sale of Property, Plant & Equipment	0.00	0.00	0.00
Sale and/or Maturity of Investments	612	647	356
Net Cash From Financing Activities	270	35	290
Net Cash From Continuing Financing Activities	270	35	290
Issuance of Preferred Equity	0.00	0.00	0.00
Issuance of Common Equity	270	35	290

This table details how cash moves in and out of Relay Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-28	18	-19	9.13	-7.59	5.43	-15	9.48	-203	247
Net Cash From Operating Activities	-58	-75	-66	-50	-89	-75	-69	-67	-57	-66
Net Cash From Continuing Operating Activities	-58	-75	-66	-50	-89	-75	-69	-67	-57	-66
Net Income / (Loss) Continuing Operations	-76	-88	-92	-81	-83	-66	-99	-94	-68	-84
Consolidated Net Income / (Loss)	-76	-88	-92	-81	-83	-66	-99	-94	-68	-84
Depreciation Expense	1.33	1.37	1.37	1.40	1.38	1.36	1.33	1.20	1.17	1.03
Amortization Expense	-2.18	-3.18	-3.29	-3.67	-3.67	-2.88	-2.20	-2.02	-0.39	0.34
Non-Cash Adjustments To Reconcile Net Income	18	22	27	27	19	22	23	22	14	14
Changes in Operating Assets and Liabilities, net	1.45	-7.65	1.47	6.15	-23	-30	7.36	6.41	-4.17	2.94
Net Cash From Investing Activities	29	-126	46	11	60	71	51	75	-147	27
Net Cash From Continuing Investing Activities	29	-126	46	11	60	71	51	75	-147	27
Purchase of Investments	-75	-265	-120	-191	-137	-85	-66	-98	-328	-56
Sale and/or Maturity of Investments	104	139	165	203	197	157	119	175	183	85
Net Cash From Financing Activities	0.80	219	1.54	49	22	9.46	2.08	1.30	1.17	286
Net Cash From Continuing Financing Activities	0.80	219	1.54	49	22	9.46	2.08	1.30	1.17	286
Issuance of Common Equity	0.80	219	1.54	49	22	9.46	2.08	1.30	2.30	286

This table presents Relay Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	871	844	1,100
Total Current Assets	809	770	1,020
Cash & Equivalents	124	144	152
Short-Term Investments	657	606	847
Prepaid Expenses	17	17	12
Other Current Assets	11	3.32	8.17
Plant, Property, & Equipment, net	5.91	11	12
Total Noncurrent Assets	56	63	69
Intangible Assets	2.30	2.30	2.30
Other Noncurrent Operating Assets	54	61	66
Total Liabilities & Shareholders' Equity	871	844	1,100
Total Liabilities	94	92	150
Total Current Liabilities	51	30	64
Accounts Payable	14	9.21	11
Accrued Expenses	21	15	23
Current Deferred Revenue	7.68	0.00	-
Other Current Liabilities	7.72	6.17	30
Total Noncurrent Liabilities	43	62	86
Capital Lease Obligations	43	49	53
Other Noncurrent Operating Liabilities	0.00	13	32
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	778	752	950
Total Preferred & Common Equity	778	752	950
Preferred Stock	0.00	0.00	0.00
Total Common Equity	778	752	950
Common Stock	2,517	2,153	2,019
Retained Earnings	-1,738	-1,401	-1,059
Accumulated Other Comprehensive Income / (Loss)	-0.99	-0.20	-10

This table presents Relay Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	930	773	841	907	962	1,038	1,169
Total Current Assets	865	704	770	832	884	958	1,087
Cash & Equivalents	152	134	153	151	146	161	355
Short-Term Investments	687	554	597	659	726	777	699
Prepaid Expenses	19	10	13	17	9.31	11	17
Other Current Assets	6.80	5.73	7.30	3.68	3.39	9.03	16
Plant, Property, & Equipment, net	7.21	8.35	9.88	11	12	12	11
Total Noncurrent Assets	58	60	61	64	66	67	70
Intangible Assets	2.30	2.30	2.30	2.30	2.30	2.30	2.30
Other Noncurrent Operating Assets	55	58	59	62	64	65	68
Total Liabilities & Shareholders' Equity	930	773	841	907	962	1,038	1,169
Total Liabilities	91	91	96	129	152	154	169
Total Current Liabilities	47	45	37	51	72	70	71
Accounts Payable	6.87	11	7.97	13	15	12	9.49
Accrued Expenses	33	28	22	31	27	28	29
Other Current Liabilities	6.89	6.10	6.81	5.89	30	31	33
Total Noncurrent Liabilities	44	46	59	78	80	84	98
Capital Lease Obligations	44	46	47	50	51	-	55
Other Noncurrent Operating Liabilities	0.00	0.00	11	28	29	84	43
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	839	682	746	778	810	883	1,000
Total Preferred & Common Equity	839	682	746	778	810	883	1,000
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	839	682	746	778	810	883	1,000
Common Stock	2,499	2,257	2,229	2,099	2,068	2,042	2,004
Retained Earnings	-1,662	-1,574	-1,482	-1,317	-1,251	-1,153	-991
Accumulated Other Comprehensive Income / (Loss)	2.51	-1.34	-1.16	-3.39	-6.08	-5.80	-13

This table displays calculated financial ratios and metrics derived from Relay Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-60.83%	1,749.82%	-54.41%
EBITDA Growth	-0.21%	-28.75%	18.05%
EBIT Growth	0.15%	-24.63%	17.93%
NOPAT Growth	0.14%	-24.63%	17.94%
Net Income Growth	1.25%	-17.72%	20.16%
EPS Growth	15.41%	-7.72%	32.20%
Operating Cash Flow Growth	17.05%	-30.86%	-208.43%
Free Cash Flow Firm Growth	18.65%	-11.74%	-150.04%
Invested Capital Growth	-22.16%	957.67%	107.91%
Revenue Q/Q Growth	0.01%	-0.98%	-18.53%
EBITDA Q/Q Growth	2.23%	-6.29%	-2.11%
EBIT Q/Q Growth	1.90%	-5.46%	-1.75%
NOPAT Q/Q Growth	1.90%	-5.47%	-1.74%
Net Income Q/Q Growth	2.17%	-4.91%	-0.02%
EPS Q/Q Growth	9.23%	-4.10%	1.52%
Operating Cash Flow Q/Q Growth	11.17%	-11.97%	-8.19%
Free Cash Flow Firm Q/Q Growth	14.46%	-15.95%	-19.17%
Invested Capital Q/Q Growth	-9.86%	186.91%	726.17%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-3,790.40%	-1,481.69%	-21,287.69%
Operating Margin	-3,722.07%	-1,460.11%	-21,670.89%
EBIT Margin	-3,721.93%	-1,460.18%	-21,672.34%
Profit (Net Income) Margin	-3,374.72%	-1,338.66%	-21,036.13%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	90.67%	91.68%	97.06%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-581.57%	-946.25%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-570.88%	-936.43%	0.00%
Return on Net Nonoperating Assets (RNNOA)	537.42%	906.07%	0.00%
Return on Equity (ROE)	-44.15%	-40.18%	-31.44%
Cash Return on Invested Capital (CROIC)	-556.65%	-1,111.70%	-5,758.85%
Operating Return on Assets (OROA)	-43.43%	-38.38%	-28.39%
Return on Assets (ROA)	-39.38%	-35.19%	-27.56%
Return on Common Equity (ROCE)	-44.15%	-40.18%	-31.44%
Return on Equity Simple (ROE_SIMPLE)	-43.42%	-45.48%	-30.57%
Net Operating Profit after Tax (NOPAT)	-261	-261	-209
NOPAT Margin	-2,605.45%	-1,022.08%	-15,169.62%
Net Nonoperating Expense Percent (NNEP)	-10.69%	-9.82%	-8.51%
Return On Investment Capital (ROIC_SIMPLE)	-31.77%	-32.62%	-20.87%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	765.38%	293.39%	4,777.55%
R&D to Revenue	3,188.66%	1,291.86%	17,838.88%
Operating Expenses to Revenue	3,822.07%	1,560.11%	21,770.89%
Earnings before Interest and Taxes (EBIT)	-372	-373	-299
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-379	-379	-294
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.89	1.80	1.90
Price to Tangible Book Value (P/TBV)	0.89	1.81	1.91
Price to Revenue (P/Rev)	68.91	53.13	1,307.87
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	13.00	180.56
Enterprise Value to Revenue (EV/Rev)	0.00	25.66	623.26
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.06	0.06	0.06
Long-Term Debt to Equity	0.06	0.06	0.06
Financial Leverage	-0.94	-0.97	-1.03
Leverage Ratio	1.12	1.14	1.14
Compound Leverage Factor	1.02	1.05	1.11
Debt to Total Capital	5.21%	6.06%	5.33%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	5.21%	6.06%	5.33%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	94.79%	93.94%	94.67%
Debt to EBITDA	-0.11	-0.13	-0.18
Net Debt to EBITDA	1.95	1.85	3.22
Long-Term Debt to EBITDA	-0.11	-0.13	-0.18
Debt to NOPAT	-0.16	-0.19	-0.26
Net Debt to NOPAT	2.83	2.69	4.51
Long-Term Debt to NOPAT	-0.16	-0.19	-0.26
Altman Z-Score	1.28	6.15	6.04
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	15.95	25.44	16.00
Quick Ratio	15.40	24.78	15.68
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-250	-307	-275
Operating Cash Flow to CapEx	-12,344.25%	-7,278.62%	-2,532.44%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.01	0.03	0.00
Accounts Receivable Turnover	0.00	0.00	3.90
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	1.19	2.27	0.15
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	93.69
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	93.69
Capital & Investment Metrics	-	-	-
Invested Capital	39	50	4.77
Invested Capital Turnover	0.22	0.93	-0.05
Increase / (Decrease) in Invested Capital	-11	46	65
Enterprise Value (EV)	-49	656	861
Market Capitalization	690	1,357	1,806
Book Value per Share	$4.65	$6.10	$7.86
Tangible Book Value per Share	$4.63	$6.08	$7.84
Total Capital	821	801	1,004
Total Debt	43	49	53
Total Long-Term Debt	43	49	53
Net Debt	-739	-702	-945
Capital Expenditures (CapEx)	2.02	4.13	9.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-23	-10	-43
Debt-free Net Working Capital (DFNWC)	758	740	956
Net Working Capital (NWC)	758	740	956
Net Nonoperating Expense (NNE)	77	81	81
Net Nonoperating Obligations (NNO)	-739	-702	-945
Total Depreciation and Amortization (D&A)	-6.85	-5.49	5.31
Debt-free, Cash-free Net Working Capital to Revenue	-228.32%	-40.13%	-3,122.45%
Debt-free Net Working Capital to Revenue	7,579.44%	2,896.09%	69,210.43%
Net Working Capital to Revenue	7,579.44%	2,896.09%	69,210.43%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.36)	($2.79)	($2.59)
Adjusted Weighted Average Basic Shares Outstanding	142.87M	122.58M	112.23M
Adjusted Diluted Earnings per Share	($2.36)	($2.79)	($2.59)
Adjusted Weighted Average Diluted Shares Outstanding	142.87M	122.58M	121.38M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	169.52M	131.18M	121.38M
Normalized Net Operating Profit after Tax (NOPAT)	-261	-261	-209
Normalized NOPAT Margin	-2,605.45%	-1,022.08%	-15,169.62%
Pre Tax Income Margin	-3,374.72%	-1,338.66%	-21,036.13%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Relay Therapeutics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-100.00%	-100.00%	4,327.88%	-100.40%	7,226.16%	-67.40%	-46.06%	-55.38%	-48.35%
EBITDA Growth	9.17%	-30.76%	3.97%	9.21%	-31.06%	11.15%	-40.16%	-66.98%	-9.22%	-42.50%
EBIT Growth	7.83%	-30.99%	5.00%	10.72%	-26.51%	14.33%	-36.34%	-61.26%	-7.61%	-40.82%
NOPAT Growth	7.83%	-30.98%	4.99%	10.69%	-26.55%	14.34%	-36.29%	-61.31%	-7.57%	-40.83%
Net Income Growth	8.97%	-34.03%	6.39%	13.64%	-23.69%	21.91%	-28.28%	-51.89%	-0.07%	-38.37%
EPS Growth	36.36%	-16.67%	14.81%	20.51%	-20.00%	28.95%	-14.08%	-36.84%	6.78%	-15.15%
Operating Cash Flow Growth	35.12%	0.42%	4.03%	25.04%	-56.25%	-13.99%	-20.16%	-36.52%	-43.75%	-24.34%
Free Cash Flow Firm Growth	56.16%	-36.38%	-17.38%	-209.04%	5.03%	19.01%	-118.39%	-3,280.60%	-218.29%	-350.86%
Invested Capital Growth	-22.16%	147.76%	477.48%	179.63%	957.67%	2,945.58%	72.98%	-52.56%	107.91%	102.42%
Revenue Q/Q Growth	0.00%	0.00%	-100.00%	1,000,800.00%	-100.00%	21,078.15%	-47.35%	-10.67%	-26.45%	-5.75%
EBITDA Q/Q Growth	12.59%	4.37%	-10.88%	1.99%	-25.83%	29.78%	-4.83%	-41.48%	14.69%	-10.78%
EBIT Q/Q Growth	11.83%	4.35%	-11.54%	2.01%	-25.30%	30.63%	-4.83%	-38.84%	15.15%	-10.40%
NOPAT Q/Q Growth	11.82%	4.36%	-11.50%	1.99%	-25.31%	30.62%	-4.82%	-38.88%	15.18%	-10.39%
Net Income Q/Q Growth	13.73%	4.45%	-13.30%	2.52%	-27.02%	33.27%	-4.53%	-39.61%	19.80%	-9.62%
EPS Q/Q Growth	33.33%	8.70%	-11.29%	6.06%	-22.22%	33.33%	-3.85%	-41.82%	27.63%	-7.04%
Operating Cash Flow Q/Q Growth	22.93%	-14.05%	-30.82%	43.58%	-18.29%	-9.91%	-2.19%	-17.61%	13.71%	-15.85%
Free Cash Flow Firm Q/Q Growth	48.29%	22.13%	25.46%	-46.08%	-60.86%	32.98%	-96.24%	55.11%	-37.19%	-80.71%
Invested Capital Q/Q Growth	-9.86%	11.37%	-9.75%	-14.09%	186.91%	269.69%	80.96%	-1,241.01%	726.17%	101.51%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	0.00%	0.00%	0.00%	-925.43%	0.00%	-297.96%	-89,857.98%	-45,132.74%	-28,495.65%	-24,567.44%
Operating Margin	0.00%	0.00%	0.00%	-903.00%	0.00%	-291.95%	-89,117.65%	-44,768.58%	-28,794.86%	-24,968.60%
EBIT Margin	0.00%	0.00%	0.00%	-902.75%	0.00%	-291.96%	-89,129.41%	-44,769.91%	-28,804.35%	-24,966.57%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	-813.30%	0.00%	-260.83%	-82,777.31%	-41,698.67%	-26,681.03%	-24,468.60%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	89.44%	91.42%	91.52%	90.09%	90.56%	89.34%	92.87%	93.14%	92.63%	98.01%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-581.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	-579.39%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	573.47%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	0.00%	0.00%	-40.40%	0.00%	-7.53%	-43.33%	-37.41%	-31.44%	-36.98%
Cash Return on Invested Capital (CROIC)	-556.65%	-954.80%	-765.56%	-810.89%	-1,111.70%	-2,915.20%	0.00%	0.00%	-5,758.85%	-39,922.86%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	-33.95%	0.00%	-7.26%	-90.70%	-53.52%	-37.74%	-45.99%
Return on Assets (ROA)	0.00%	0.00%	0.00%	-30.58%	0.00%	-6.48%	-84.23%	-49.85%	-34.96%	-45.07%
Return on Common Equity (ROCE)	0.00%	0.00%	0.00%	-40.40%	0.00%	-7.53%	-43.33%	-37.41%	-31.44%	-36.98%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-41.15%	-47.35%	-44.13%	0.00%	-41.88%	-42.51%	-36.53%	0.00%	-29.05%
Net Operating Profit after Tax (NOPAT)	-59	-67	-71	-63	-65	-52	-74	-71	-51	-60
NOPAT Margin	0.00%	0.00%	0.00%	-632.10%	0.00%	-204.36%	-62,382.35%	-31,338.01%	-20,156.40%	-17,478.02%
Net Nonoperating Expense Percent (NNEP)	-2.29%	-2.65%	-2.96%	-2.21%	-2.30%	-1.62%	-2.96%	-2.58%	-1.73%	-3.02%
Return On Investment Capital (ROIC_SIMPLE)	-7.25%	-	-	-	-8.06%	-	-	-	-5.08%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	197.85%	0.00%	73.35%	16,907.56%	8,663.27%	6,470.75%	4,672.67%
R&D to Revenue	0.00%	0.00%	0.00%	823.45%	0.00%	323.36%	74,118.49%	36,649.12%	26,591.70%	19,447.67%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	1,003.00%	0.00%	391.95%	89,217.65%	44,868.58%	28,894.86%	25,068.60%
Earnings before Interest and Taxes (EBIT)	-85	-96	-101	-90	-92	-74	-106	-101	-73	-86
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-86	-98	-103	-93	-94	-75	-107	-102	-72	-85
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.89	1.13	1.27	1.37	1.80	1.32	1.89	2.26	1.90	2.44
Price to Tangible Book Value (P/TBV)	0.89	1.13	1.27	1.38	1.81	1.32	1.89	2.27	1.91	2.44
Price to Revenue (P/Rev)	68.91	94.74	24.58	28.96	53.13	39.81	1,621.51	1,682.83	1,307.87	1,437.20
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	3.51	5.70	7.40	13.00	15.16	0.00	0.00	180.56	2,490.22
Enterprise Value to Revenue (EV/Rev)	0.00	15.25	6.33	9.08	25.66	10.32	750.52	893.44	623.26	847.70
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.06	0.05	0.07	0.06	0.06	0.06	0.06	0.00	0.06	0.05
Long-Term Debt to Equity	0.06	0.05	0.07	0.06	0.06	0.06	0.06	0.00	0.06	0.05
Financial Leverage	-0.94	-0.96	-0.98	-1.01	-0.97	-0.99	-1.03	-1.05	-1.03	-1.01
Leverage Ratio	1.12	1.14	1.16	1.15	1.14	1.17	1.16	1.15	1.14	1.17
Compound Leverage Factor	1.00	1.04	1.06	1.04	1.03	1.04	1.08	1.07	1.06	1.15
Debt to Total Capital	5.21%	5.01%	6.29%	5.95%	6.06%	6.01%	5.93%	0.00%	5.33%	5.18%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	5.21%	5.01%	6.29%	5.95%	6.06%	6.01%	5.93%	0.00%	5.33%	5.18%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	94.79%	94.99%	93.71%	94.05%	93.94%	93.99%	94.07%	100.00%	94.67%	94.82%
Debt to EBITDA	-0.11	-0.11	-0.13	-0.13	-0.13	-0.14	-0.14	0.00	-0.18	-0.19
Net Debt to EBITDA	1.95	2.05	1.76	1.90	1.85	2.14	2.24	0.00	3.22	3.47
Long-Term Debt to EBITDA	-0.11	-0.11	-0.13	-0.13	-0.13	-0.14	-0.14	0.00	-0.18	-0.19
Debt to NOPAT	-0.16	-0.17	-0.18	-0.19	-0.19	-0.20	-0.20	0.00	-0.26	-0.27
Net Debt to NOPAT	2.83	2.99	2.57	2.77	2.69	3.07	3.20	0.00	4.51	4.85
Long-Term Debt to NOPAT	-0.16	-0.17	-0.18	-0.19	-0.19	-0.20	-0.20	0.00	-0.26	-0.27
Altman Z-Score	2.37	4.46	3.51	4.68	7.25	3.55	4.86	6.93	6.72	8.27
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	15.95	18.42	15.64	20.73	25.44	16.39	12.36	13.60	16.00	15.22
Quick Ratio	15.40	17.88	15.28	20.18	24.78	15.98	12.18	13.31	15.68	14.76
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-48	-93	-120	-161	-110	-68	-102	-52	-116	-85
Operating Cash Flow to CapEx	0.00%	-33,076.21%	-598,481.82%	-2,827.13%	-75,583.05%	-12,779.15%	-4,564.27%	-3,505.48%	-2,464.55%	-3,157.28%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.01	0.01	0.04	0.04	0.03	0.02	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	114.16	5.15	4.28	3.90	3.24
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.19	1.12	3.50	3.24	2.27	2.34	0.09	0.11	0.15	0.19
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	3.20	70.91	85.26	93.69	112.51
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	3.20	70.91	85.26	93.69	112.51
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	39	44	39	43	50	18	-10	-54	4.77	0.58
Invested Capital Turnover	0.22	0.33	2.45	-6.38	0.93	2.84	-0.04	-0.03	-0.05	-0.15
Increase / (Decrease) in Invested Capital	-11	26	49	98	46	17	28	-19	65	24
Enterprise Value (EV)	-49	153	223	321	656	266	707	1,061	861	1,437
Market Capitalization	690	948	865	1,023	1,357	1,027	1,527	1,999	1,806	2,436
Book Value per Share	$4.65	$6.27	$5.14	$5.70	$6.10	$6.37	$6.66	$7.28	$7.86	$9.18
Tangible Book Value per Share	$4.63	$6.25	$5.12	$5.68	$6.08	$6.35	$6.64	$7.26	$7.84	$9.16
Total Capital	821	883	728	793	801	828	861	883	1,004	1,054
Total Debt	43	44	46	47	49	50	51	0.00	53	55
Total Long-Term Debt	43	44	46	47	49	50	51	0.00	53	55
Net Debt	-739	-795	-643	-702	-702	-761	-820	-938	-945	-999
Capital Expenditures (CapEx)	0.00	0.23	0.01	1.78	0.12	0.59	1.50	1.92	2.32	2.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-23	-21	-29	-17	-10	-30	-59	-50	-43	-38
Debt-free Net Working Capital (DFNWC)	758	818	659	733	740	781	813	888	956	1,016
Net Working Capital (NWC)	758	818	659	733	740	781	813	888	956	1,016
Net Nonoperating Expense (NNE)	17	21	22	18	19	14	24	23	17	24
Net Nonoperating Obligations (NNO)	-739	-795	-643	-702	-702	-761	-820	-938	-945	-999
Total Depreciation and Amortization (D&A)	-0.85	-1.81	-1.92	-2.27	-2.29	-1.51	-0.87	-0.82	0.78	1.37
Debt-free, Cash-free Net Working Capital to Revenue	-228.32%	-214.35%	-82.90%	-47.14%	-40.13%	-114.59%	-6,242.04%	-4,198.91%	-3,122.45%	-2,237.29%
Debt-free Net Working Capital to Revenue	7,579.44%	8,176.70%	1,872.38%	2,074.78%	2,896.09%	3,027.33%	86,281.63%	74,740.82%	69,210.43%	59,933.33%
Net Working Capital to Revenue	7,579.44%	8,176.70%	1,872.38%	2,074.78%	2,896.09%	3,027.33%	86,281.63%	74,740.82%	69,210.43%	59,933.33%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.42)	($0.63)	($0.69)	($0.62)	($0.66)	($0.54)	($0.81)	($0.78)	($0.55)	($0.76)
Adjusted Weighted Average Basic Shares Outstanding	142.87M	140.23M	132.82M	130.84M	122.58M	122.23M	121.68M	121.32M	112.23M	110.91M
Adjusted Diluted Earnings per Share	($0.42)	($0.63)	($0.69)	($0.62)	($0.66)	($0.54)	($0.81)	($0.78)	($0.55)	($0.76)
Adjusted Weighted Average Diluted Shares Outstanding	142.87M	140.23M	132.82M	130.84M	122.58M	122.23M	121.68M	121.32M	112.23M	110.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	169.52M	167.38M	133.89M	132.74M	131.18M	123.27M	122.13M	121.61M	121.38M	120.89M
Normalized Net Operating Profit after Tax (NOPAT)	-59	-67	-71	-63	-65	-52	-74	-71	-51	-60
Normalized NOPAT Margin	0.00%	0.00%	0.00%	-632.10%	0.00%	-204.36%	-62,382.35%	-31,338.01%	-20,156.40%	-17,478.02%
Pre Tax Income Margin	0.00%	0.00%	0.00%	-813.30%	0.00%	-260.83%	-82,777.31%	-41,698.67%	-26,681.03%	-24,468.60%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Relay Therapeutics' Financials

When does Relay Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Relay Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Relay Therapeutics' net income changed over the last 2 years?

Relay Therapeutics' net income appears to be on an upward trend, with a most recent value of -$337.71 million in 2024, rising from -$290.51 million in 2022. The previous period was -$341.97 million in 2023. Find out what analysts predict for Relay Therapeutics in the coming months.

What is Relay Therapeutics's operating income?

Relay Therapeutics's total operating income in 2024 was -$372.47 million, based on the following breakdown:

Total Gross Profit: $10.01 million
Total Operating Expenses: $382.48 million

How has Relay Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Relay Therapeutics' total revenue changed from $1.38 million in 2022 to $10.01 million in 2024, a change of 624.6%.

How much debt does Relay Therapeutics have?

Relay Therapeutics' total liabilities were at $93.50 million at the end of 2024, a 1.7% increase from 2023, and a 37.5% decrease since 2022.

How much cash does Relay Therapeutics have?

In the past 2 years, Relay Therapeutics' cash and equivalents has ranged from $124.29 million in 2024 to $151.79 million in 2022, and is currently $124.29 million as of their latest financial filing in 2024.

How has Relay Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Relay Therapeutics' book value per share changed from 7.86 in 2022 to 4.65 in 2024, a change of -40.9%.

Related Companies

This page (NASDAQ:RLAY) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relay Therapeutics (RLAY) Financials

Frequently Asked Questions About Relay Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relay Therapeutics (RLAY) Financials

Annual Income Statements for Relay Therapeutics

Quarterly Income Statements for Relay Therapeutics

Annual Cash Flow Statements for Relay Therapeutics

Quarterly Cash Flow Statements for Relay Therapeutics

Annual Balance Sheets for Relay Therapeutics

Quarterly Balance Sheets for Relay Therapeutics

Annual Metrics And Ratios for Relay Therapeutics

Quarterly Metrics And Ratios for Relay Therapeutics

Frequently Asked Questions About Relay Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools